|
![]() |
|||
|
||||
OverviewFull Product DetailsAuthor: Christopher M. Riley (President of Riley and Rabel Consulting Services, Maryville, MO, USA) , Thomas W. Rosanske (Consultatnt, Lee's Summit, MO, USA) , George L. Reid (Principal Consultant, Cardinal Health, Kansas City, MO, USA)Publisher: Elsevier Health Sciences Imprint: Elsevier / The Lancet Edition: 2nd edition Weight: 1.540kg ISBN: 9780081028247ISBN 10: 0081028245 Pages: 694 Publication Date: 24 July 2020 Audience: College/higher education , Tertiary & Higher Education Replaced By: 9780443134661 Format: Paperback Publisher's Status: Active Availability: Manufactured on demand ![]() We will order this item for you from a manufactured on demand supplier. Table of ContentsReviewsAuthor InformationDr. Christopher Riley is the President of Riley and Rabel Consulting Services. He received a bachelor’s degree in Pharmacy (1977) and PhD degree in Pharmaceutical Chemistry (1980) from the University of Bath, UK. He taught Pharmaceutical Chemistry, at the Universities of Florida (1983-6) and the University of Kansas (1986-94), and was a Vice President at DuPont Merck (1994-2001) and ALZA (a division of J&J) (2001-7). He has coauthored more than 140 book chapters and papers in peer-reviewed journals, as well as 5 books. He has extensive experience in CMC regulatory affairs and the development of all types of dosage forms. Former Director of Business Development at Acceleration Laboratory Services, Incorporated. He has previously held scientific and senior management positions at The Upjohn Company, Marion Laboratories, Marion Merrell Dow, Hoechst Marion Roussel, Quintiles, Eli Lilly, Beckloff Associates, and PPD. He currently serves on a Small Molecule USP Expert Committee. Tab Content 6Author Website:Countries AvailableAll regions |